The estimated Net Worth of Konstantinos Alataris is at least $143 Tausend dollars as of 20 March 2017. Konstantinos Alataris owns over 127,389 units of Zosano Pharma Corp stock worth over $142,676 and over the last 9 years Konstantinos sold ZSAN stock worth over $0.
Konstantinos has made over 2 trades of the Zosano Pharma Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently Konstantinos exercised 127,389 units of ZSAN stock worth $184,714 on 20 March 2017.
The largest trade Konstantinos's ever made was exercising 127,389 units of Zosano Pharma Corp stock on 20 March 2017 worth over $184,714. On average, Konstantinos trades about 50,956 units every 43 days since 2015. As of 20 March 2017 Konstantinos still owns at least 254,778 units of Zosano Pharma Corp stock.
You can see the complete history of Konstantinos Alataris stock trades at the bottom of the page.
Konstantinos's mailing address filed with the SEC is 34790 Ardentech Ct, Fremont, CA 94555, USA.
Over the last 10 years, insiders at Zosano Pharma Corp have traded over $5,506,679 worth of Zosano Pharma Corp stock and bought 790,627 units worth $1,835,090 . The most active insiders traders include M James Barrett, Enterprise Associates 12, L... und Steve Elms. On average, Zosano Pharma Corp executives and independent directors trade stock every 60 days with the average trade being worth of $44,258. The most recent stock trade was executed by Christine Matthews on 6 June 2022, trading 82 units of ZSAN stock currently worth $58.
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.
Zosano Pharma Corp executives and other stock owners filed with the SEC include: